Cargando…
High-Throughput Screening Methodology to Identify Alpha-Synuclein Aggregation Inhibitors
An increasing number of neurodegenerative diseases are being found to be associated with the abnormal accumulation of aggregated proteins in the brain. In Parkinson’s disease, this process involves the aggregation of alpha-synuclein (α-syn) into intraneuronal inclusions. Thus, compounds that inhibit...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5372494/ https://www.ncbi.nlm.nih.gov/pubmed/28257086 http://dx.doi.org/10.3390/ijms18030478 |
_version_ | 1782518628674961408 |
---|---|
author | Pujols, Jordi Peña-Díaz, Samuel Conde-Giménez, María Pinheiro, Francisca Navarro, Susanna Sancho, Javier Ventura, Salvador |
author_facet | Pujols, Jordi Peña-Díaz, Samuel Conde-Giménez, María Pinheiro, Francisca Navarro, Susanna Sancho, Javier Ventura, Salvador |
author_sort | Pujols, Jordi |
collection | PubMed |
description | An increasing number of neurodegenerative diseases are being found to be associated with the abnormal accumulation of aggregated proteins in the brain. In Parkinson’s disease, this process involves the aggregation of alpha-synuclein (α-syn) into intraneuronal inclusions. Thus, compounds that inhibit α-syn aggregation represent a promising therapeutic strategy as disease-modifying agents for neurodegeneration. The formation of α-syn amyloid aggregates can be reproduced in vitro by incubation of the recombinant protein. However, the in vitro aggregation of α-syn is exceedingly slow and highly irreproducible, therefore precluding fast high throughput anti-aggregation drug screening. Here, we present a simple and easy-to-implement in-plate method for screening large chemical libraries in the search for α-syn aggregation modulators. It allows us to monitor aggregation kinetics with high reproducibility, while being faster and requiring lower protein amounts than conventional aggregation assays. We illustrate how the approach enables the identification of strong aggregation inhibitors in a library of more than 14,000 compounds. |
format | Online Article Text |
id | pubmed-5372494 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-53724942017-04-10 High-Throughput Screening Methodology to Identify Alpha-Synuclein Aggregation Inhibitors Pujols, Jordi Peña-Díaz, Samuel Conde-Giménez, María Pinheiro, Francisca Navarro, Susanna Sancho, Javier Ventura, Salvador Int J Mol Sci Article An increasing number of neurodegenerative diseases are being found to be associated with the abnormal accumulation of aggregated proteins in the brain. In Parkinson’s disease, this process involves the aggregation of alpha-synuclein (α-syn) into intraneuronal inclusions. Thus, compounds that inhibit α-syn aggregation represent a promising therapeutic strategy as disease-modifying agents for neurodegeneration. The formation of α-syn amyloid aggregates can be reproduced in vitro by incubation of the recombinant protein. However, the in vitro aggregation of α-syn is exceedingly slow and highly irreproducible, therefore precluding fast high throughput anti-aggregation drug screening. Here, we present a simple and easy-to-implement in-plate method for screening large chemical libraries in the search for α-syn aggregation modulators. It allows us to monitor aggregation kinetics with high reproducibility, while being faster and requiring lower protein amounts than conventional aggregation assays. We illustrate how the approach enables the identification of strong aggregation inhibitors in a library of more than 14,000 compounds. MDPI 2017-03-02 /pmc/articles/PMC5372494/ /pubmed/28257086 http://dx.doi.org/10.3390/ijms18030478 Text en © 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Pujols, Jordi Peña-Díaz, Samuel Conde-Giménez, María Pinheiro, Francisca Navarro, Susanna Sancho, Javier Ventura, Salvador High-Throughput Screening Methodology to Identify Alpha-Synuclein Aggregation Inhibitors |
title | High-Throughput Screening Methodology to Identify Alpha-Synuclein Aggregation Inhibitors |
title_full | High-Throughput Screening Methodology to Identify Alpha-Synuclein Aggregation Inhibitors |
title_fullStr | High-Throughput Screening Methodology to Identify Alpha-Synuclein Aggregation Inhibitors |
title_full_unstemmed | High-Throughput Screening Methodology to Identify Alpha-Synuclein Aggregation Inhibitors |
title_short | High-Throughput Screening Methodology to Identify Alpha-Synuclein Aggregation Inhibitors |
title_sort | high-throughput screening methodology to identify alpha-synuclein aggregation inhibitors |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5372494/ https://www.ncbi.nlm.nih.gov/pubmed/28257086 http://dx.doi.org/10.3390/ijms18030478 |
work_keys_str_mv | AT pujolsjordi highthroughputscreeningmethodologytoidentifyalphasynucleinaggregationinhibitors AT penadiazsamuel highthroughputscreeningmethodologytoidentifyalphasynucleinaggregationinhibitors AT condegimenezmaria highthroughputscreeningmethodologytoidentifyalphasynucleinaggregationinhibitors AT pinheirofrancisca highthroughputscreeningmethodologytoidentifyalphasynucleinaggregationinhibitors AT navarrosusanna highthroughputscreeningmethodologytoidentifyalphasynucleinaggregationinhibitors AT sanchojavier highthroughputscreeningmethodologytoidentifyalphasynucleinaggregationinhibitors AT venturasalvador highthroughputscreeningmethodologytoidentifyalphasynucleinaggregationinhibitors |